Autopsy report · NCT02519270

Phase 1, Dose-Escalation Study of IGN002 in NHL Subjects

“Strategic Reasons”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 2 years before it stopped.
• 62 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 1

Sponsor

Spectrum Pharmaceuticals, Inc

Sponsor type

Industry

Conditions

Non-Hodgkin Lymphoma

Interventions

IGN002

Participants

62

Sites

2

Countries

United States

Trials that died the same way

• Efficacy and Safety of Atorvastatin + Perindopril Fixed-Dose Combination S05167 in Adult Patients With Arterial Hypertension and Dyslipidemia
  “for strategic reasons” (90% match in meaning)
• S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
  “Strategic development reasons” (87% match in meaning)
• Study of ONO-7914 Alone and in Combination With ONO-4538 in Patients With Solid Tumors
  “Due to strategic reasons” (86% match in meaning)
• Duodenal Exclusion for the Treatment of Type 2 Diabetes
  “business reasons” (78% match in meaning)
• A Study to Determine Safety, Tolerability, Pharmacokinetics, and Recommended Phase 2 Dose (RP2D) of Intravenous ABBV-184 in Adult Participants With Previously Treated Cancers
  “Strategic considerations” (77% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.